Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non–Small Cell Lung or Colorectal Cancer

作者：Kenneth L. Kehl, Gregory J. Riely, Eva M. Lepisto, Jessica A. Lavery, Jeremy L. Warner, Michele L. Lenoue-Newton, Shawn M. Sweeney, Julia E. Rudolph, Samantha Brown, Celeste Yu, Philippe L. Bédard, Deborah Schrag, Katherine S. Panageas, Shawn M. Sweeney, Margaret Foti, Yekaterina B. Khotskaya, Michael V. Fiandalo, Benjamin E. Gross, Nikolaus Schultz, Brooke Mastrogiacomo, Mahdi Sarmardy, Marilyn M. Li, Adam Resnick, Angela J. Waanders, Jena Lilly, Richard D. Carvajal, Raúl Rabadán, Matthew Ingham, Susan Hsaio, Jean Abraham, James D. Brenton, Oscar M. Rueda, Carlos Caldas, Mikel Valgañón, Dilrini De Silva, Chris Boursnell, Raquel Rodríguez-García, E. Vargaz Rodriguez, Birgit Nimmervoll, Ethan Cerami, Matthew D. Ducar, Priti Kumari, Neal I. Lindeman, Laura MacConnaill, John A. Orechia, Deborah Schrag, Priyanka Shivdasani, Eliezer M. Van Allen, Jason M. Johnson, Pasi A. Jänne, Eva M. Lepisto, Michael J. Hassett, Sindy Pimentel, Parin Sripakdeevong, Katherine A. Janeway, Jason M. Johnson, Matthew Meyerson, Daniel M. Quinn, Oya Cushing, Kevin M. Haigis, Diana Miller, Kenneth L. Kehl, Alexander Gustav, Angela C. Tramontano, Simon Arango Baquero, Jonathan L. Bell, Michelle Green, Shannon J. McCall, Michael Datto, Fabien Calvo, Fabrice André, Meurice Guillaume, Semih Doğan, Lacroix Ludovic, Jean Scoazec, Monica Ardenos, Gilles Vassal, Stefan Michels, Victor E. Velculescu, Alexander S. Baras, Christopher D. Gocke, Julie R. Brahmer, Charles L. Sawyers, David B. Solit, Stuart M. Gardos, Mike Berger, Marc Ladanyi, Gregory J. Riely, S. Joseph Sirintrapun, Ari Caroline, Stacy B. Thomas, Andrew Zarski, Ahmet Zehir, Alexia Iasonosa, John Philip, Samantha Brown, Andrew L. Kung, Ritika Kundra, Julia E. Rudolph, Jessica A. Lavery, Hira Rivzi, J. Schwartz, Caroline McCarthy, Maufur Bhuiya, Axel Martin, Cynthia Chu, Raymond DuBois, Tony van de Velde, Gerrit A. Meijer, Hugo M. Horlings, Harm van Tinteren, Martijn P. Lolkema, Les Nijman, Mariska Bierkens, Jelle ten Hoeve, Emilie Voest, Annemieke C. Hiemstra, Gabe S. Sonke, Jacques Craenmehr, Jan Hudeček, Kim Monkhorst, Walter J. Urba, Brady Bernard, Brian Piening, Carlo Bifulco, Paul Tittel, Julie Cramer, Justin Guinney, Celeste Yu, Xindi Guo, Alyssa Acebedo, Philip W. Gold, Neil A. Bailey, Sabah Kadri, Jeremy P. Segal, Wanjari Pankhuri, Peng Wang, Steinhardt George, Moung Christine, Laura van’t Veer, Eric Talevich, Amanda Wren, E. Alejandro Sweet‐Cordero, Michelle L. Turski, Philippe L. Bédard, Suzanne Kamel‐Reid, Zhibin Lu, Trevor J. Pugh, Lillian L. Siu, Stuart Watt, Natasha B. Leighl, Celeste Yu, Lailah Ahmed, Geeta Krishna, Carlos Virtaenen, Helen Chow, Demi Plagianakos, Samantha Del Rossi, Nitthusha Singaravelan, Sevan Hakgor, Nazish Qazi, Alisha Nguyen, Natalie Stickle, Thomas Stricker, Christine Micheel, Ingrid Anderson, Leigh F. Jones, Lucy Lu Wang, Christine M. Lovly, Michele LeNoue Newton, Ben Park, Jeremy L. Warner, Daniel Fabbri, Joseph Coco, Chen Ye, Sandip Chaugai, Sanjay Mishra, Yuanchu James Yang, Wen Li, Rodrigo Dienstmann, Susana Aguilar Izquierdo, Cristina Viaplana Donato, Francesco M. Mancuso, Ümit Topaloĝlu, Liang Liu, Meijian Guan, Wei Zhang, Guangxu Jin, James C. Knight, Michael D’Eletto, E. Zeynep Ormay, Shrikant Mane, Kaya Bilgüvar, Walther Zenta, Daniel Dykas · 发表于：JAMA Network Open · 年份：2021 · DOI：10.1001/jamanetworkopen.2021.17547 · 被引用次数：40 · 研究领域：Cancer Genomics and Diagnostics、Lung Cancer Treatments and Mutations、Lung Cancer Diagnosis and Treatment

Importance: Contemporary observational cancer research requires associating genomic biomarkers with reproducible end points; overall survival (OS) is a key end point, but interpretation can be challenging when multiple lines of therapy and prolonged survival are common. Progression-free survival (PFS), time to treatment discontinuation (TTD), and time to next treatment (TTNT) are alternative end points, but their utility as surrogates for OS in real-world clinicogenomic data sets has not been well characterized. Objective: To measure correlations between candidate surrogate end points and OS in a multi-institutional clinicogenomic data set. Design, Setting, and Participants: A retrospective cohort study was conducted of patients with non-small cell lung cancer (NSCLC) or colorectal cancer (CRC) whose tumors were genotyped at 4 academic centers from January 1, 2014, to December 31, 2017, and who initiated systemic therapy for advanced disease. Patients were followed up through August 31, 2020 (NSCLC), and October 31, 2020 (CRC). Statistical analyses were conducted on January 5, 2021. Exposures: Candidate surrogate end points included TTD; TTNT; PFS based on imaging reports only; PFS based on medical oncologist ascertainment only; PFS based on either imaging or medical oncologist ascertainment, whichever came first; and PFS defined by a requirement that both imaging and medical oncologist ascertainment have indicated progression. Main Outcomes and Measures: The primary outcome ...